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Abstract
Purpose:  To  compare  the  capabilities  of  apparent  diffusion  coefﬁcient  (ADC)  and  normalized
ADC using  the  pancreatic  parenchyma  as  reference  organ  in  the  characterization  of  focal  pan-
creatic lesions.
Patients  and  methods:  Thirty-six  patients  with  focal  pancreatic  lesions  (malignant,  n  =  18;
benign tumors,  n  =  10;  focal  pancreatitis,  n  =  8)  underwent  diffusion-weighted  MR  imaging  (DWI)
at 1.5-Tesla  using  3  b  values  (b  =  0,  400,  800  s/mm2).  Lesion  ADC  and  normalized  lesion  ADC
(deﬁned as  the  ratio  of  lesion  ADC  to  apparently  normal  adjacent  pancreas)  were  comparedcharacterization between  lesion  types  using  nonparametric  tests.
Results:  Signiﬁcant  differences  in  ADC  values  were  found  between  malignant
(1.150 ×  10 −3 mm2/s)  and  benign  tumors  (2.493  ×  10−3 mm2/s)  (P  =  0.004)  and  between
−3 2benign tumors  and  mass-forming  pancreatitis  (1.160  ×  10 mm /s)  (P  =  0.0005)  but  not
between malignant  tumors  and  mass-forming  pancreatitis  (P  =  0.1092).  Using  normalized  ADC,
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signiﬁcant  differences  were  found  between  malignant  tumors  (0.933  ×  10−3 mm2/s),  benign
tumors (1.807  ×  10−3 mm2/s)  and  mass-forming  pancreatitis  (0.839  ×  10−3 mm2/s)  (P  <  0.0001).
Conclusion:  Our  preliminary  results  suggest  that  normalizing  ADC  of  focal  pancreatic  lesions
with ADC  of  apparently  normal  adjacent  pancreatic  parenchyma  provides  higher  degrees  of
characterization  of  focal  pancre
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scopic  ultrasound-guided  biopsy  (n  =  3)  or  percutaneous© 2013  Éditions  françaises  d
iffusion-weighted  magnetic  resonance  imaging  (DWI)  with
uantitative  measurement  of  apparent  diffusion  coefﬁcient
ADC)  values  has  a  well-established  role  for  the  diagnosis  of
 variety  of  abdominal  abnormalities  [1—7].  Regarding  pan-
reatic  disease,  several  researchers  have  demonstrated  that
WI  with  ADC  measurement  helps  detect  and  further  char-
cterize  focal  pancreatic  lesions  [8—11]  as  well  as  assess
he  severity  of  other  pancreatic  conditions  [12,13]. How-
ver,  individual  studies  found  conﬂicting  results  with  respect
o  the  capabilities  of  ADC  measurement  in  differentiating
etween  pancreatic  cancers  and  mass-forming  pancreati-
is  [14—16],  mostly  because  of  an  overlap  in  ADC  values
etween  these  two  entities  [17].
To  limit  the  possible  inﬂuence  of  technical  parameters  on
he  resulting  ADC  value,  researchers  have  used  a  normalized
DC  to  improve  characterization  of  pathologic  conditions
ith  DWI  [18,19].  However,  this  approach  has  not  been
valuated  yet  for  the  characterization  of  focal  pancreatic
esions.
Accordingly,  we  performed  this  study  to  compare  the
apabilities  of  apparent  diffusion  coefﬁcient  (ADC)  with
hose  of  normalized  ADC  using  the  pancreatic  parenchyma  as
eference  in  the  characterization  of  focal  pancreatic  lesions.
atients and methods
atientshis  retrospective  study  was  performed  according  to  the
eview  board  guidelines  of  our  institution  and  informed
Table  1  Demographic  data  of  three  groups  of  patients  with  fo
Malignant  tumors  (n  =  18)  Be
Gender  distribution  (M/F)  11/7  5/
Age  (years)
Median  62  51
Q1—Q3 55—69  48
Range  36—80  23
Lesion  location
Head  9  6  
Neck  0  1  
Body  5  2  
Tail  4  1  
Lesion  size  (mm)
Median  32.5  27
Q1—Q3  26—40  25
Range  16—56  15
Q1: lower quartile; Q3: upper quartile; M: male; F: female.
c
o
catic  lesions  than  the  conventional  ADC  does.
diologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
onsent  was  obtained  from  all  patients.  From  January  2010
hrough  January  2012,  the  MR  imaging  databases  of  two  Uni-
ersity  Hospitals  were  retrospectively  queried  to  identify  all
dult  patients  referred  for  MR  imaging  of  the  pancreas  at
.5-T.  The  electronic  archiving  systems  of  both  institutions
ere  then  used  to  retrieve  the  subgroup  of  patients  who
ad  focal  pancreatic  lesions,  as  evidenced  by  the  results  of
istopathological  analysis  either  after  surgery,  endoscopic
iopsy  or  percutaneous  biopsy.
The  study  population  consisted  of  36  patients  (23  males
nd  13  females)  with  a  mean  age  of  56  years  ±  12.6  years
SD)  (range:  21—80  years)  who  underwent  DWI  examination
f  the  pancreas  at  1.5-T.
Eighteen  patients  (50%)  had  malignant  pancreatic  tumors
hat  consisted  in  13  adenocarcinomas  (including  seven
ell-differentiated,  three  moderately  and  three  poorly
ifferentiated  adenocarcinomas)  and  ﬁve  non-secreting
euroendocrine  tumors,  10  patients  (28%)  had  benign
umors  of  the  pancreas  that  consisted  in  seven  serous  cys-
adenomas,  two  solid  pseudopapillary  neoplasms  and  one
ucinous  cystadenoma,  and  eight  patients  (22%)  had  focal,
ass-forming  pancreatitis  that  consisted  in  ﬁve  chronic  pan-
reatitis  and  three  auto-immune  pancreatitis.  The  gender
nd  age  distribution  in  each  group  of  patients  are  described
n  Table  1.
The  diagnosis  of  pancreatic  cancer  was  histopatho-
ogically  conﬁrmed  after  surgical  resection  (n  =  9),  endo-cal  pancreatic  lesions.
nign  tumors  (n  =  10)  Mass-forming  pancreatitis  (n  =  8)
5  7/1
.5  52.5
—58  43—55
—79  39—63
3
0
2
3
 33.5
—35  24—42
—80  20—48
omputed-tomography  guided  biopsy  (n  =  6).  The  diagnosis
f  mass-forming  chronic  pancreatitis  was  histopathologi-
ally  conﬁrmed  after  surgical  resection  (n  =  2)  or  endoscopic
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tCharacterization  of  focal  pancreatic  lesions  
ultrasound-guided  biopsy  and  a  follow-up  of  at  least  10-
months  (n  =  3).  The  diagnosis  of  mass-forming  auto-immune
pancreatitis  was  made  on  the  basis  of  histopathologi-
cal  analysis  after  endoscopic  ultrasound-guided  biopsy  and
a  favorable  response  to  steroid  therapy.  The  diagnosis
of  serous  and  mucinous  cystadenoma  was  histopathologi-
cally  conﬁrmed  after  surgical  resection.  The  diagnosis  of
solid  pseudopapillary  neoplasm  was  made  after  surgical
resection;  both  were  considered  non-malignant  but  with
uncertain  potential  for  malignancy,  with  complete  encap-
sulation  and  without  atypia  [20,21].  For  all  patients,  the
time  interval  between  DWI  and  histopathological  conﬁr-
mation  was  less  than  10  days  (mean,  3.4  days;  range,
1—9  days).
MR examination protocol
All  patients  underwent  MR  imaging  examination  of  the
abdomen  using  a  1.5-T  system  (Magnetom  Avanto®,  Siemens
Healthcare,  Erlangen,  Germany,  running  software  Syngo  MR
B15).  High-resolution  free-breathing  T2-weighted  fast  spin-
echo  sequence  with  respiratory  triggering  using  prospective
acquisition  correction  and  three-dimensional  volumetric
interpolated  breath-hold  gradient-echo  (3D  VIBE)  sequence
before  and  after  intravenous  administration  of  a  gadolinium-
chelate  were  obtained  in  all  patients  in  addition  to  DWI
sequence.  All  imaging  examinations  were  performed  with  a
nine-channel  anterior  phased-array  coil  and  a  nine-channel
posterior  phased-array  coil.  Patients  were  imaged  in  supine
position.
DWI  was  performed  with  a  fat-suppressed  single-shot
spin-echo  echo-planar  diffusion-weighted  technique  in  the
axial  plane  with  three  gradient  factors  (b  values  =  0,  400
and  800  s/mm2)  within  the  same  acquisition.  The  diffu-
sion  gradients  were  applied  in  three  orthogonal  directions
along  the  three  main  axes  of  the  magnet  bore  (i.  e.,  fre-
quency,  phase  and  slice  select  directions).  The  single-shot
echo-planar  imaging  readout  was  preceded  by  a  diffusion-
sensitizing  block  consisting  of  two  180◦ radiofrequency
pulses.  Parallel  imaging  with  generalized  autocalibrat-
ing  partially  parallel  acquisition  (GRAPPA)  was  used  with
an  acceleration  factor  (or  reduction  factor)  of  2.  Fat
suppression  consisted  of  a  spectral  adiabatic  inversion-
recovery  (SPAIR)  technique  [22].  DWI  was  obtained  using
a  respiratory-triggered  acquisition  and  prior  to  gadolinium-
chelate  administration  in  all  patients.  The  other  parameters
were  as  follows:  repetition  time/echo  time,  5300  ms/75  ms;
echo  spacing,  0.69  ms;  matrix  size,  182  ×  192;  6/8  partial
Fourier  acquisition;  section  thickness,  6  mm;  intersection
gap,  1  mm;  voxel  size,  2.1  ×  2.0  ×  6.0  mm;  ﬁeld  of  view
380  mm;  number  of  signal  averages,  4;  echo-planar  imag-
ing  factor,  148;  receiver  bandwidth,  1736  Hz/pixel;  30  axial
sections  acquired;  acquisition  time,  257  s.  Imaging  datasets
were  reconstructed  using  a  GRAPPA-based  algorithm.  No
speciﬁc  bowel  preparation  was  used  before  MR  exami-
nation  and  no  antispasmodic  agents  were  given  to  the
patients.Image analysis
MR  images  were  analyzed  using  a  commercially  avail-
able  workstation  (MMWP  with  the  Syngo  Software,  Siemens
r
t
c621
ealthcare)  by  two  observers  (one  fourth-year  resident  in
adiology  and  one  radiologist  with  21  years  of  experience
n  interpreting  abdominal  MR  images)  working  in  consensus,
linded  to  the  histological  nature  of  the  focal  pancreatic
esions.  For  each  focal  pancreatic  lesion,  largest  axial  diam-
ter  and  location  were  recorded.
The  two  observers  placed  regions  of  interest  (ROIs)
o  encompass  as  much  as  possible  of  each  focal  pancre-
tic  lesion  on  the  diffusion-weighted  images  obtained  with
 =  0  s/mm2.  However,  a  1-mm  peripheral  margin  of  focal
ancreatic  lesion  was  left  outside  the  ROI  to  avoid  including
djacent  pancreatic  parenchyma  within  the  ROI.  During  the
ame  session,  circular  ROIs  with  a  minimum  size  of  100  pix-
ls  were  placed  on  each  of  the  four  pancreatic  segments.
pecial  care  was  given  to  avoid  pancreatic  vessels,  pan-
reatic  ducts,  calciﬁcations  and  artifacts  in  ROI  placement.
he  ROIs  were  then  transferred  from  the  b0 images  to  the
DC  maps  by  using  the  ‘‘copy-and-paste’’  function  of  the
orkstation.
The  ADC  maps  were  generated  automatically  from  the
ource  data  using  the  integrated  Syngo  software  and  ADC
alues  were  calculated  with  three  b  values,  including  the
 =  0,  400  and  800  values  s/mm2 using  a  mono-exponential
tting  algorithm  [23]. Because  the  b  =  0  value  was  included
or  ADC  calculation,  the  resulting  ADC  was  the  ADCto-
al  and  we  did  not  separate  perfusion  and  true  diffusion
ffects  [16,23]. ADC  and  normalized  ADC  were  calculated.
ormalized  ADC  was  deﬁned  as  the  ratio  of  focal  pancre-
tic  lesion  ADC  to  apparently  normal  adjacent  pancreas
DC.
The  four  pancreatic  segments  were  deﬁned  as  follows:
he  head  was  deﬁned  as  the  pancreatic  segment  located
etween  the  superior  mesenteric  vein  and  the  gastroduode-
al  artery,  that  lies  to  the  right  of  the  superior  mesenteric
rtery;  the  neck  (or  isthmus)  was  the  thin  section  between
he  head  and  the  body  of  the  gland  that  lies  anterior  to  the
onﬂuence  of  the  superior  mesenteric  vein  and  splenic  vein,
hich  grooves  its  posterior  aspect;  the  body  was  deﬁned
s  the  longest  portion  of  the  pancreas,  extending  from  the
eck  and  passing  to  the  tail,  lying  to  the  left  of  the  superior
esenteric  vessels;  the  tail  was  deﬁned  as  the  ﬁnal  portion
f  the  left  pancreas,  that  lies  anterior  to  the  left  kidney
djacent  to  the  splenic  hilum  [24].
tatistical analysis
esion  sizes  and  results  of  ADC  measurements  for  each
ocal  pancreatic  lesion  and  pancreatic  parenchyma  were
xpressed  as  medians,  ﬁrst  quartiles  (q1),  third  quartiles
q3)  and  ranges.  Lesion  sizes,  ADC  and  normalized  ADC  val-
es  were  compared  between  subgroups  of  focal  pancreatic
esions  with  the  Kruskal-Wallis  test  for  overall  compari-
on  and  the  Wilcoxon  signed  rank  test  was  used  when
verall  comparison  was  signiﬁcant.  Pairwise  comparisons
f  the  ADC  values  obtained  for  the  different  pancre-
tic  segments  were  made  using  the  Wilcoxon  signed  rank
est.R  software  (version  2.8,  R  Foundation,  http://www.
-project.org/)  was  used  for  statistical  analysis.  All  statis-
ical  tests  were  two-tailed  and  statistical  signiﬁcance  was
onsidered  at  P  <  0.05.
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Results
Largest  axial  diameters  of  focal  pancreatic  lesions  as  well
as  lesion  location  with  respect  to  speciﬁc  pancreatic  seg-
ment  are  reported  in  Table  1.  No  signiﬁcant  differences  in
lesion  size  were  found  between  the  three  groups  of  focal
pancreatic  lesions  (P  =  0.775).
No  signiﬁcant  differences  in  ADC  values  were  found
between  the  four  pancreatic  segments  (Tables  2  &  3).  Sim-
ilarly,  no  differences  in  ADC  values  of  apparently  healthy
pancreatic  parenchyma  were  found  between  the  three
groups  of  focal  pancreatic  lesions  (Table  4).
Signiﬁcant  differences  in  ADC  values  were  found  between
malignant  tumors  (1.150  ×  10−3 mm2/s)  (Fig.  1)  and  benign
tumors  (2.493  ×  10−3 mm2/s)  (Figs.  2  &  3) (P  =  0.004)  and
between  benign  tumors  and  mass-forming  pancreatitis
(1.160  ×  10−3 mm2/s)  (Fig.  4)  (P  =  0.0005)  but  not  between
malignant  tumors  and  mass-forming  pancreatitis  (P  =  0.1092)
(Table  5).  In  addition,  overlap  in  ADC  values  between  the
three  subgroups  of  focal  pancreatic  lesions  was  observed
(Fig.  5).
Using  normalized  ADC,  signiﬁcant  differences  were  found
between  malignant  tumors  (0.933  ×  10−3 mm2/s),  benign
tumors  (1.807  ×  10−3 mm2/s)  and  mass-forming  pancreatitis
(0.839  ×  10−3 mm2/s)  (P  <  0.0001).  Table  6  shows  normal-
ized  ADC  of  pancreatic  lesions  according  to  lesion  type.  By
Figure 1. Sixty-year-old man with poorly differentiated adeno-
carcinoma of the pancreatic head. Axial ADC map shows focal
pancreatic lesion (arrow). ADC of the lesion is 1.201 × 10−3 mm2/s
and ADC of adjacent pancreatic parenchyma is 1.289 × 10−3 mm2/s.
The resulting normalized ADC of the pancreatic tumor is 0.931.
Figure 2. Forty-nine year-old man with benign serous cystade-
noma of the pancreas. Axial apparent diffusion coefﬁcient (ADC)
map shows focal pancreatic lesion (arrow). ADC of the lesion is
2.663 × 10−3 mm2/s and ADC of adjacent pancreatic parenchyma
is 1.253 × 10−3 mm2/s. The resulting normalized ADC of the pan-
creatic tumor is 2.125.
Figure 3. Twenty-three year-old man with benign solid pseu-
dopapillary tumor of the pancreas. Axial apparent diffusion
coefﬁcient (ADC) map shows focal pancreatic lesion (arrow). ADC
of the lesion is 1.562 × 10−3 mm2/s and ADC of adjacent pancreatic
parenchyma is 1.285 × 10−3 mm2/s. The resulting normalized ADC
of the pancreatic tumor is 1.215.
Table  2  ADC  (×  10−3 mm2/s)  of  apparently  disease-free  pancreatic  segments  in  36  patients  with  focal  pancreatic  lesions.
ADC  Value  Head  Neck  Body  Tail
Median  1.218  1.276  1.299  1.291
Q1—Q3  1.056—1.405  1.177—1.443  1.160—1.418  1.113—1.484
Range  0.656—1.814  0.921—1.642  0.446—1.976  0.580—2.176
Q1: lower quartile; Q3: upper quartile. Apparent diffusion coefﬁcient (ADC) indicates apparent diffusion coefﬁcient. No signiﬁcant
differences in ADC values were found between the four pancreatic segments (Kruskall-Wallis test).
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Table  3  P  values  for  comparisons  of  ADC  values  of
apparently  disease-free  parenchyma  between  the  four
pancreatic  segments  in  36  patients  with  focal  pancreatic
lesions.
Segments  P  value
Head  vs.  Neck 0.0553
Head  vs.  Body 0.0854
Head  vs.  Tail 0.0758
Neck  vs.  Body  0.6771
Neck  vs.  Tail  0.4747
Body  vs.  Tail  0.2998
ADC: apparent diffusion coefﬁcient. Comparisons were made
using the Wilcoxon signed ranked test.
Figure 4. Sixty-three year-old man with chronic pancreatitis of
the pancreatic head. Axial apparent diffusion coefﬁcient (ADC)
map shows focal pancreatic lesion (arrow). ADC of the lesion is
0.940 × 10−3 mm2/s and ADC of adjacent pancreatic parenchyma
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ccomparison  with  ADC,  less  degrees  of  overlap  in  normalized
ADC  were  observed  (Fig.  6).
Discussion
As  stressed  recently,  one  major  limitation  of  DWI  is  the  difﬁ-
culty  to  differentiate  between  pancreatic  adenocarcinoma
and  mass-forming  pancreatitis  because  of  overlap  in  ADC
values  [17].  Our  preliminary  results  show  that  normalized
ADC  helps  characterize  focal  pancreatic  lesions  and  further
discriminate  between  pancreatic  cancers  and  mass-forming
pancreatitis.  In  our  study,  the  use  of  the  conventional  ADC
was  less  discriminating  because  of  marked  overlap  in  ADC
values  between  these  two  entities,  and  this  was  consistent
with  the  results  of  other  researchers  [23].  The  results  of
our  study  show  that  ADC  measurements  using  a  normalized
f
n
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Table  4  ADC  (×  10−3 mm2/s)  of  apparently  disease-free  panc
pancreatic  lesions.
Subgroup  Head  Ne
Malignant  tumors
Median  1.238  1.
Q1—Q3  1.048—1.465  1.
Range  0.656—1814  0.
Mean  1.158  1.
Benign  tumors
Median  1.215  1.
Q1—Q3 1.163—1.296  1.
Range  0.898—1.479 1.
Mean  1.213  1.
Mass-forming  pancreatitis
Median  1.291  1.
Q1—Q3  0.924—1.405  1.
Range  0.696—1.530  0.
Mean  1.214  1.
Q1: lower quartile; Q3: upper quartile. Apparent diffusion coefﬁcien
differences in ADC values of pancreatic segments were found between
test).s 1.113 × 10−3 mm2/s. The resulting normalized ADC of the mass-
orming pancreatitis is 0.847.
DC  is  more  discriminating  than  the  more  common  ADC  to
ifferentiate  between  focal  pancreatic  lesions,  and  more
peciﬁcally  between  malignant  pancreatic  tumors  and  mass-
orming  pancreatitis.
Recent  studies  have  evaluated  the  capabilities  of  ADC
easurement  in  discriminating  between  malignant  and
enign  pancreatic  conditions  and  other  have  determined  to
hat  extent  ADC  measurement  helps  grade  the  severity  of
hronic  pancreatitis  [10—12].  In  this  regard,  some  authors
ound  that  malignant  pancreatic  tumors  have  ADC  values  sig-
iﬁcantly  lower  than  that  of  normal  pancreatic  parenchyma
s  observed  in  our  study  [11,16].
reatic  parenchyma  in  three  groups  of  patients  with  focal
ck  Body  Tail
260  1.264  1.277
138—1.449  1.101—1.460  1.110—1.487
921—1.642  0.446—1.976  0.580—2.176
240  1.265  1.161
258  1.273  1.298
209—1.349  1.160—1.326  1.113—1.525
060—1.600  1.048—1.725  1.018—1.885
308  1.304  1.347
277  1.334  1.343
194—1.443  1.298—1.388  1.214—1.456
938—1.470  0.953—1.653  1.031—1.469
245  1.329  1.316
t (ADC) indicates apparent diffusion coefﬁcient. No signiﬁcant
 the three groups of patients (0.7739 < P < 0.9405; Kruskal-Wallis
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Table  5  ADC  (×  10−3 mm2/s)  values  of  pancreatic  lesions  in  three  groups  of  patients  with  focal  pancreatic  lesions.
ADC  value  Malignant  tumors  Benign  tumors  Mass-forming  pancreatitis
Median  1.150  2.493  1.160
Q1—Q3  0.994—1.350  1.434—2.760  1.047—1.231
Range  0.673—1.596  1.121—2.804  0.780—1.222
Q1: lower quartile; Q3: upper quartile. Apparent diffusion coefﬁcient (ADC) indicates apparent diffusion coefﬁcient. Signiﬁcant differ-
ences in ADC values were found between the three groups of patients (P = 0.0014; Kruskal-Wallis test) because of signiﬁcant difference
between malignant and benign tumors (P = 0.004) and between benign tumors and mass-forming pancreatitis (P = 0.0005). Conversely,
no differences were found between malignant tumors and mass-forming pancreatitis (P = 0.1092).
Table  6  Normalized  ADC  (×  10−3 mm2/s)  of  pancreatic  lesions  in  three  groups  of  patients  with  focal  pancreatic  lesions.
ADC  value  Malignant  tumors  Benign  tumors  Mass-forming  pancreatitis
Median  0.933  1.807  0.839
Q1—Q3  0.907—0.954  1.248—1.919  0.759—0.878
Range  0.895—0.985  1.131—2.17  0.708—0.890
Q1: lower quartile; Q3: upper quartile. Apparent diffusion coefﬁcient (ADC) indicates apparent diffusion coefﬁcient. Signiﬁcant dif-
ferences in ADC values were found between the three groups of patients (P < 0.0001; Kruskal-Wallis test) with a signiﬁcant difference
between malignant and benign tumors (P < 0.0001), between benign tumors and mass-forming pancreatitis (P < 0.0001) and between
malignant tumors and mass-forming pancreatitis (P = 0.0144).
Several  groups  have  investigated  the  potential  role
of  ADC  measurement  in  discriminating  between  malig-
nant  pancreatic  tumors  and  mass-forming  pancreatitis
[14—16,25,26].  As  reported  recently  by  Vermoolen  et  al.
[27],  inconsistencies  were  found  between  studies.  Whereas
Lee  et  al.  [16]  and  Takeuchi  et  al.  [25]  found  lower  ADC  val-
ues  in  benign  pancreatic  lesions  by  comparison  with  those
observed  in  malignant  ones,  reversed  results  were  reported
by  Fattahi  et  al.  [14],  Kartalis  et  al.  [15]  and  Yamashita  et  al.
[26].  Our  results  mirror  those  reported  by  Lee  et  al.  who
found  that  ADC  of  pancreatic  cancers  and  mass-forming  pan-
creatitis  obtained  at  either  b  =  500  s/mm2 or  b  =  1000  s/mm2
Figure 5. Box plots of apparent diffusion coefﬁcient (ADC) val-
ues of focal pancreatic lesions, which differed signiﬁcantly between
benign lesions and the other two subtypes but not between mass-
forming pancreatitis and malignant tumors. Boxes stretch across
interquartile range (IR), i. e., from lower quartile (Q1) to upper
quartile (Q3). Blue dots indicate outliers.
were  signiﬁcantly  lower  than  that  of  pancreatic  parenchyma
of  control  patients  without  pancreatic  disease  [16].  Con-
versely,  the  same  group  observed  lower  ADC  values  for
mass-forming  pancreatitis  by  comparison  with  pancreatic
cancer,  although  we  did  not  ﬁnd  such  difference  in  our  study
using  ADC.  By  contrast,  we  found  such  differences  between
these  two  conditions  using  normalized  ADC  only.
Previous  studies  have  reported  ADC  values  of
the  normal  pancreas  using  parallel  imaging  at  1.5-
T  and  marked  variations  were  found  among  studies.
Using  a  free-breathing  technique  without  respiratory
triggering  and  that  included  b0 for  ADC  calculation
(0  s/mm2 ≤  b  ≤  800  s/mm2),  Rosenkrantz  et  al.  found  mean
Figure 6. Box plots of normalized apparent diffusion coefﬁcient
(ADC) values of focal pancreatic lesions, which differed signiﬁcantly
between the three types of focal pancreatic lesions. Boxes stretch
across interquartile range (IR), i. e., from lower quartile (Q1) to
upper quartile (Q3). Blue dots indicate outliers.
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ADC  values  of  1.26  ×  10−3 mm2/s  at  1.5-T  for  normal
pancreatic  parenchyma,  which  are  close  to  the  overall
ADC  values  we  found,  irrespective  to  the  type  of  focal
pancreatic  lesion  being  present  [22].  Conversely,  using  a
breath-hold  technique  at  1.5-T  with  two  b  values  of  50-
and  500-s/mm2,  Wiggermann  et  al.  found  a  very  low  ADC  of
0.17  ×  10−3 mm2/s  [10].  Using  a  free-breathing  technique
at  1.5-T  and  three  b  values  of  0-,  500-  and  1000-s/mm2,
another  group  of  researchers  found  ADC  values  ranging
from  1.59  ×  10−3 mm2/s  to  1.68  ×  10-3 mm2/s  for  normal
pancreatic  parenchyma,  with  no  signiﬁcant  differences
between  the  three  pancreatic  segments  (head,  body  and
tail)  [28].  It  has  been  assumed  that  variations  in  ADC  values
may  be  the  results  of  differences  in  patient  population,
imaging  sequences,  selection  of  speciﬁc  b  values  for  ADC
calculation,  or  other  technical  acquisition  parameters  such
as  slice  thickness  [10,28,29].  In  addition,  calculation  of  ADC
values  may  be  inﬂuenced  by  the  inclusion  of  low  b  values  as
explained  by  the  intravoxel  incoherent  motion  (IVIM)  theory
[30,31].  In  our  study,  for  a  given  ROI,  we  obtained  a  total
ADC  value  that  consisted  in  the  added  results  of  diffusion
and  microperfusion  effects.  The  effect  of  microperfusion
on  the  resulting  total  ADC  is  more  prominent  using  low  b
values  [32].
In  our  study,  we  found  that  the  apparently  normal
parenchyma  showed  homogeneous  distribution  of  ADC  val-
ues  among  the  four  pancreatic  segments,  in  accordance  with
the  results  of  other  studies  [33].  However,  we  are  aware  of
a  study  in  which  the  pancreatic  tail  had  lower  ADC  value  by
comparison  with  the  head  and  the  body  [34].
Pancreatic  adenocarcinoma  is  usually  associated  with  low
ADC  values  by  comparison  with  those  of  healthy  pancre-
atic  parenchyma  because  of  the  presence  of  ﬁbrosis  and
increased  cellularity,  which  are  associated  with  restricted
water  diffusion  [35].  However,  necrosis,  which  is  a  frequent
component  of  pancreatic  adenocarcinoma,  is  responsible  for
increased  ADC  values  due  to  increased  random  motion  of
water  molecules  [35].  Consequently,  variations  in  ADC  found
among  individual  studies  may  be  due  to  marked  differences
in  the  relative  proportions  of  ﬁbrosis  and  necrosis  and  degree
of  cellularity  within  the  tumors.
Differentiation  between  mass-forming  pancreatitis  and
pancreatic  cancer  with  conventional  ADC  measurement
is  not  so  straightforward  because  of  inconsistencies  and
conﬂicting  results  between  published  studies  [17].  Some
studies  reported  greater  ADC  values  for  mass-forming
pancreatitis  than  for  pancreatic  cancers  [14,15],  others
reported  greater  ADC  values  for  pancreatic  cancers  than
for  mass-forming  pancreatitis  [16,25]  whereas  we  and  oth-
ers  did  not  ﬁnd  any  signiﬁcant  differences  in  ADC  values
between  these  two  conditions  [10,23].  One  reason  may  be
that  mass-forming  pancreatitis  may  contain  variable  pro-
portions  of  ﬁbrosis  and  inﬂammation,  which  may  explain
variations  among  studies  and  overlap  in  ADC  values  between
mass-forming  pancreatitis  and  pancreatic  cancers  [36].
In  our  preliminary  study,  we  have  deﬁned  a  normalized
ADC  using  the  pancreatic  parenchyma  as  reference.  ADC  nor-
malization  has  been  deﬁned  already  in  the  abdomen  using
the  spleen  as  a  reference  organ  [18].  We  preferred  using  the
adjacent  pancreatic  parenchyma  for  normalization  because
measurements  were  made  easier  with  ROIs  used  for  calcu-
lation  placed  on  the  same  level  of  slice  and  because  we625
ssumed  that  the  adjacent  parenchyma  was  subjected  to
he  same  ﬁeld  heterogeneity  and  susceptibility  effects  than
he  lesion.  However,  we  agree  upon  the  fact  that  the  appar-
ntly  healthy  pancreatic  parenchyma  used  for  normalization
ay  be  involved  at  some  degrees  by  the  underlying  pancre-
tic  disease.  In  this  regard,  Momtahen  et  al.  found  lower
DC  values  for  the  pancreatic  parenchyma  of  disease-free
atients  than  for  that  of  patients  with  mass-forming  pan-
reatitis  [36].
Our  study  has  several  limitations.  First,  our  results  were
btained  from  a  limited  cohort  study,  reﬂecting  our  prelim-
nary  experience.  Second,  we  used  a  respiratory-triggered
echnique  for  DWI  so  that  our  results  may  apply  only  for
his  speciﬁc  acquisition  technique  [37,38].  A  third  limita-
ion  is  that  we  only  calculated  ADC  total.  We  agree  that
urther  studies  should  be  done  to  address  this  concern  and
hat  the  IVIM  model  should  be  applied  to  investigate  the
iscriminating  capabilities  of  the  perfusion  fraction  (f)  and
he  perfusion  free  diffusion  parameter  (D)  [39,40].  Similarly,
urther  studies  should  be  done  to  investigate  at  what  extent
he  number  of  b  values  may  modify  normalized  ADC  [1,5].
In  conclusion,  our  preliminary  results  suggest  that  nor-
alizing  ADC  of  focal  pancreatic  lesions  with  ADC  of
pparently  normal  adjacent  pancreatic  parenchyma  allows
o  discriminate  between  different  types  of  focal  pancreatic
esions.  Further  studies,  however,  are  needed  to  fully  eval-
ate  to  what  extent  normalized  ADC  can  be  used  to  fully
haracterize  focal  pancreatic  lesions.  In  addition,  our  pre-
iminary  results  obtained  in  a  relatively  small  population
hould  warrant  further  conﬁrmation  by  larger  prospective
rials.
TAKE-HOME  MESSAGES
• signiﬁcant  differences  in  normalized  ADC  values  exist
between  focal  pancreatic  lesion  subtypes;
• normalized  ADC  improves  characterization  of  focal
pancreatic  lesions;
• normalized  ADC  should  be  preferred  to  conventional
ADC.
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